bluebird bio, Inc (BLUE): Price Target Chart

Symbol and logo of brand Bluebird Bio (BLUE)

The price history of bluebird bio, Inc. (BLUE) reflects the dynamics of an asset valued at 8.00. Exclusive patents for complex treatment methods and stringent FDA oversight serve as business protections. Environmental policy focuses on the safe disposal of chemical reagents, while profits are generated through the sale of high-cost single-dose injections via insurance funds and government agencies.

Analyst Consensus Forecast: Bluebird Bio (BLUE) for 07/04/2022 - 06/07/2025
Manufactured products of bluebirdbio.com

The consensus forecast aggregates target prices from leading investment banks, filtering out market noise to identify the true fundamental value trend of the asset. By analyzing the current consensus valuation level, an investor gains a weighted average of market expectations, which is critically important for bluebird bio, Inc. (BLUE) given its single-product dependency and acute liquidity shortages associated with the implementation of high-cost gene therapies.

Competing companies

Price Target Chart TEM (tempus.com)|Price Target Chart Qiagen QGEN|Ionis Pharmaceuticals, Inc. - Price Target Chart|RGEN: Consensus Target|RNA - Analyst Consensus Forecast|CRSP: Analyst Consensus Forecast|Average Forecast Price genedx.com (WGS)|RARE (Ultragenyx) - Analyst Consensus Forecast|Broker Consensus Forecast BEAM (Beam Therapeutics Inc)|Price Target Chart Sarepta Therapeutics Inc (SRPT)|Twist Bioscience Corp - Broker Consensus Forecast|Analyst Consensus Forecast TXG (10x Genomics, Inc.)|Analyst Consensus Forecast intelliatx.com NTLA|Stoke Therapeutics, Inc. - Analyst Consensus Forecast|BLFS: Price Target Chart|Wave Life Sciences Corp (WVE) - Price Target Chart|MAZE (Maze Therapeutics Corp) - Price Target Chart|Consensus Target SION|Analyst Consensus Forecast primemedicine.com|Analyst Consensus Forecast TSHA|QURE - Average Forecast Price|Analyst Consensus Forecast MGTX (MeiraGTx PLC)|REGENXBIO Corp - Price Target Chart|Solid Biosciences Inc. - Analyst Consensus Forecast|Analyst Median Target ocugen.com OCGN|PacBio (PACB) - Price Target Chart|Benitec Biopharma Inc - Fair Value Consensus|DSGN (Design Pharma) - Analyst Consensus Forecast|Broker Consensus Forecast RCKT (Rocket Corp)|Consensus Target FDMT (4D Molecular Therapeutics)|LXEO (lexeotx.com) - Fair Value Consensus|Analyst Consensus Forecast KRRO (Korro Bio)|Editas Medicine Inc - Price Target Chart|Silence Therapeutics Inc. - Analyst Consensus Forecast|Analyst Median Target ProQR Therapeutics N.V. PRQR|codexis.com (CDXS) - Price Target Chart|Average Forecast Price sangamo.com (SGMO)|Consensus Target NAUT|MGX: Fair Value Consensus|Analyst Consensus Forecast DTIL|Analyst Median Target generationbio.com|Price Target Chart Boundless Bio, Inc. BOLD|XCUR: Broker Consensus Forecast|Celsion Corporation - Analyst Consensus Forecast|Phio Pharmaceuticals (PHIO) - Consensus Target|MBIO (mustangbio.com) - Consensus Target|RNAZ - Analyst Median Target|BNGO (Bionano Genomics Inc.) - Analyst Consensus Forecast|Price Target Chart APDN|Price Target Chart ImmunoPrecise Antibodies (IPA)|Price Target Chart OMGA (Omega Therapeutics Inc)|Singular Genomics Systems Inc - Consensus Target|Analyst Consensus Forecast Regulus RGLS|Syros Pharmaceuticals - Analyst Consensus Forecast|Average Forecast Price telesisbio.com|TCON: Analyst Consensus Forecast|Broker Consensus Forecast UBX